Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.35 |
| ▸ | GSK3B | P49841 | 6/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 4/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124246 | 0.81 | RIPK2 (0.43) | RIPK2TTKEGFRTP53GAA | |
| SCHEMBL7127650 | 0.73 | MAPT (0.46) | RIPK2DYRK1AGSK3BTTKTP53 | |
| SCHEMBL4786436 | 0.72 | FADS1 (0.64) | DYRK1AGSK3BCLK2FADS1TRPA1 | |
| SCHEMBL7120296 | 0.70 | RIPK2 (0.41) | RIPK2PRMT5WDR77DYRK1AGSK3B | |
| SCHEMBL7128686 | 0.70 | RIPK2 (0.47) | RIPK2EGFRTP53MAPT | |
| SCHEMBL7160086 | 0.70 | RIPK2 (0.41) | RIPK2DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL7128067 | 0.70 | ALDH1A1 (0.43) | RIPK2DYRK1AGSK3BTTKTP53 | |
| SCHEMBL7127543 | 0.69 | KDR (0.54) | EGFR | |
| SCHEMBL7125034 | 0.69 | RIPK2 (0.42) | RIPK2DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL7127458 | 0.69 | ALDH1A1 (0.42) | RIPK2TP53GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | RIPK2 3457/4885PRMT5 713/4885WDR77 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.